
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8296392/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia. Rheumatology, 2022, 61, 1709-1716.	1.9	10
2	Longâ€ŧerm risk of cancer development among <scp>antiâ€Th</scp> /To antibody–positive systemic sclerosis patients: comment on the article by Mecoli et al. Arthritis and Rheumatology, 2022, 74, 368-369.	5.6	0
3	Mutations in SAM syndrome and palmoplantar keratoderma patients suggest genotype/phenotype correlations in <i>DSG1</i> mutations. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
4	Chest computed tomography findings of adult patients with antimelanoma differentiation-associated protein 5 antibody-positive interstitial lung disease. Modern Rheumatology, 2022, 32, 365-372.	1.8	2
5	Quantitative CT analysis of interstitial pneumonia in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a single center, retrospective study. Clinical Rheumatology, 2022, 41, 1473-1481.	2.2	4
6	Case of ichthyosis with confetti caused by <scp> <i>KRT10 </i> </scp> mutation, complicated with multiple malignant melanomas. Journal of Dermatology, 2022, 49, .	1.2	1
7	Comment on: Favourable complete remission of anti-OJ antibody-positive myositis after lung cancer resection. Rheumatology, 2022, , .	1.9	2
8	Epithelioid cell granuloma formation in <i>CARD14</i> â€associated papulosquamous eruptions. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	0
9	Eosinophilic granulomatosis with polyangiitis complicated with idiopathic thrombocytopenic purpura and sclerosing cholangitis showing eosinophilic infiltration. Journal of Dermatology, 2022, 49, .	1.2	0
10	Extremely mild dominant dystrophic epidermolysis bullosa: Genotype information from wholeâ€exome sequencing of salivary <scp>gDNA</scp> predicts disease severity. Journal of Dermatology, 2022, 49, .	1.2	0
11	Response to: â€~Anti-Ku antibodies: important points to consider' by Mahler <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e183-e183.	0.9	1
12	Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age. Modern Rheumatology, 2021, 31, 177-185.	1.8	18
13	A patient with <i>CARD14</i> â€associated papulosquamous eruptions showing atopic dermatitisâ€like features. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e58-e59.	2.4	5
14	MEDNIKâ€like syndrome due to compound heterozygous mutations in <i>AP1B1</i> . Journal of the European Academy of Dermatology and Venereology, 2021, 35, e345-e347.	2.4	5
15	Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis–Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2021, 73, 677-686.	5.6	60
16	A case with overlapping features of IgG4-related autoimmune pancreatitis, Sjögren's syndrome and anti-aminoacyl-tRNA synthetase syndrome. Modern Rheumatology Case Reports, 2021, 5, 82-86.	0.7	1
17	Darier's disease with epilepsy in an elderly patient after surgery for aortic dissection. Journal of Dermatology, 2021, 48, e169-e170.	1.2	1
18	ANCAâ€associated neuropathy in systemic sclerosis: A case report and review of literature. Journal of Cutaneous Immunology and Allergy, 2021, 4, 34-36.	0.3	0

#	Article	IF	CITATIONS
19	Autoantibody profiles in patients' sera associated with distribution patterns of dermatomyositis skin symptoms. Journal of the American Academy of Dermatology, 2021, 84, 1720-1722.	1.2	2
20	Autoantibodies against the plakin family proteins as a novel marker for chronic graft-versus-host disease of the lung. Bone Marrow Transplantation, 2021, 56, 2291-2294.	2.4	0
21	Antiâ€MJ/NXPâ€2 antibodyâ€positive adultâ€onset dermatomyositis with lichen myxedematosus and endometrial carcinoma. Journal of Cutaneous Immunology and Allergy, 2021, 4, 173-174.	0.3	Ο
22	Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera. Journal of Autoimmunity, 2021, 122, 102680.	6.5	14
23	Pitfalls in establishing mouse model of female infertility by immunization with human centromere protein. Immunology Letters, 2021, 239, 20-22.	2.5	Ο
24	Antiâ€polymyositis/Scl antibodyâ€positive overlap syndrome of diffuse cutaneous systemic sclerosis, dermatomyositis, systemic lupus erythematosus, and antiphospholipid syndrome. Journal of Dermatology, 2021, , .	1.2	2
25	Autoinflammatory Keratinization Disease With Hepatitis and Autism Reveals Roles for JAK1 Kinase Hyperactivity in Autoinflammation. Frontiers in Immunology, 2021, 12, 737747.	4.8	11
26	Remodelling of calcinosis cutis in a patient with scleroderma overlap syndrome. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e20-e21.	2.4	0
27	First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. Annals of the Rheumatic Diseases, 2020, 79, 387-392.	0.9	17
28	A singleâ€centre cohort study on cutaneous manifestations of antinuclear matrix protein 2 antibodyâ€positive dermatomyositis. Clinical and Experimental Dermatology, 2020, 45, 591-593.	1.3	0
29	A case of late middle ageâ€onset recurrent rheumatic fever. Clinical and Experimental Dermatology, 2020, 45, 595-596.	1.3	1
30	Clinical and serological features of dermatomyositis and systemic lupus erythematosus patients with autoantibodies to ADAR1. Journal of Dermatological Science, 2020, 100, 82-84.	1.9	1
31	Successful treatment with i.v. immunoglobulin and rituximab for bronchiolitis obliterans associated with paraneoplastic pemphigus. Journal of Dermatology, 2020, 47, e368-e370.	1.2	4
32	Lateâ€onset Langerhans cell histiocytosis without extracutaneous involvement. Journal of Cutaneous Immunology and Allergy, 2020, 3, 94-95.	0.3	0
33	Reducing immunosuppressant use in patients with chronic inflammation during the COVIDâ€19 pandemic: Risks versus benefits. Journal of Cutaneous Immunology and Allergy, 2020, 3, 120-121.	0.3	0
34	Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab. Journal of Dermatology, 2020, 47, e217-e219.	1.2	8
35	SDR9C7 catalyzes critical dehydrogenation of acylceramides for skin barrier formation. Journal of Clinical Investigation, 2020, 130, 890-903.	8.2	54
36	Anti-Zo antibodies in Japanese myositis patients detected by a newly developed ELISA. Clinical and Experimental Rheumatology, 2020, , .	0.8	0

#	Article	IF	CITATIONS
37	Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan. Modern Rheumatology, 2019, 29, 802-807.	1.8	17
38	Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum. Clinical Rheumatology, 2019, 38, 3443-3450.	2.2	25
39	Antiphospholipid antibodyâ€positive Sjögren's syndrome with leg ulcers. Journal of Dermatology, 2019, 46, e429-e430.	1.2	1
40	Clinical characteristics of anti-Ro52α and anti-Ro52β antibodies in dermatomyositis/polymyositis. Journal of Dermatological Science, 2019, 96, 50-52.	1.9	1
41	Anti-SAE Antibody-Positive Dermatomyositis in a Japanese Patient. Journal of Clinical Rheumatology, 2019, 25, e115-e116.	0.9	7
42	Antiâ€Miâ€⊋ antibody titers and cutaneous manifestations in dermatomyositis. Journal of Cutaneous Immunology and Allergy, 2019, 2, 49-52.	0.3	3
43	Drugâ€induced acute eosinophilic pneumonia due to hydroxychloroquine in a chilblain lupus patient. Journal of Dermatology, 2019, 46, e356-e357.	1.2	5
44	Overlap of systemic lupus erythematosus and myositis is rare in anti-Ku antibody-positive patients. Annals of the Rheumatic Diseases, 2019, 80, annrheumdis-2019-216375.	0.9	13
45	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Modern Rheumatology, 2019, 29, 1-19.	1.8	28
46	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Journal of Dermatology, 2019, 46, e1-e18.	1.2	13
47	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Neurology and Clinical Neuroscience, 2019, 7, 3-21.	0.4	6
48	Prognosis of dysphagia in dermatomyositis. Clinical and Experimental Rheumatology, 2019, 37, 165.	0.8	6
49	Antiâ€ŧranscription intermediary factor 1γ antibody titer correlates with clinical symptoms in a patient with recurrent dermatomyositis associated with ovarian cancer. International Journal of Rheumatic Diseases, 2018, 21, 900-902.	1.9	5
50	Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology, 2018, 57, 1212-1221.	1.9	101
51	Fasciitis as a disease manifestation in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies: a case report of two cases. Rheumatology Advances in Practice, 2018, 2, rky015.	0.7	Ο
52	Dyschromatosis symmetrica hereditaria with chilblains due to a novel twoâ€aminoâ€acid deletion in the doubleâ€stranded <scp>RNA</scp> â€binding domain of <scp>ADAR</scp> 1. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e394-e396.	2.4	3
53	Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. Respiratory Medicine, 2018, 140, 1-5.	2.9	23
54	Strong correlation between cancer progression and anti-transcription intermediary factor 11 ³ antibodies in dermatomyositis patients. Clinical and Experimental Rheumatology, 2018, 36, 990-995.	0.8	20

#	Article	IF	CITATIONS
55	Anticentromere antibody-positive primary Sjögren's syndrome: Epitope analysis of a subset of anticentromere antibody-positive patients. Modern Rheumatology, 2017, 27, 115-121.	1.8	11
56	Rapid increase of serum antiâ€ <scp>MDA</scp> â€5 antibodies and exacerbation of clinically amyopathic dermatomyositis/interstitial lung disease. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e43-e44.	2.4	3
57	Antiâ€ <scp>PM</scp> /Scl antibodyâ€positive dermatomyositis in a Japanese patient: a case report and review of the literature. International Journal of Rheumatic Diseases, 2017, 20, 2186-2189.	1.9	8
58	Image Gallery: Palmoplantar hyperkeratosis in dermatomyositis with anti-PM/Scl antibodies. British Journal of Dermatology, 2017, 176, e94-e94.	1.5	3
59	Phosphorylated signal transducer and activator of transcription 3 in the epidermis in adultâ€onset Still's disease. Journal of Dermatology, 2017, 44, 1172-1175.	1.2	6
60	Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts. Clinica Chimica Acta, 2017, 472, 1-4.	1.1	29
61	Autoantibodies to Su/Argonaute 2 in Japanese patients with inflammatory myopathy. Clinica Chimica Acta, 2017, 471, 304-307.	1.1	8
62	Anti-dense Fine Speckled 70 Autoantibodies in Japanese Children with Dermatomyositis, Localized Scleroderma, and Idiopathic Arthritis with Iridocyclitis. Journal of Rheumatology, 2017, 44, 711-712.	2.0	3
63	Antiâ€ŧranscription intermediary factor 1â€Ĵ³ antibodyâ€positive clinically amyopathic dermatomyositis complicated by interstitial lung disease and breast cancer. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 373-375.	2.4	5
64	Antisynthetase syndrome: Pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases. European Journal of Radiology, 2016, 85, 1421-1426.	2.6	76
65	HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma. Neurology, 2016, 87, 841-843.	1.1	11
66	Serum thymus and activationâ€regulated chemokine (<scp>TARC</scp> / <scp>CCL</scp> 17) levels reflect the disease activity in a patient with bullous pemphigoid. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 327-328.	2.4	10
67	Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features—a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2016, 51, 293-302.	6.5	112
68	Ortner's syndrome caused by pulmonary arterial hypertension associated with mixed connective tissue disease. Clinical and Experimental Rheumatology, 2016, 34, 1125.	0.8	1
69	Disappearance of circulating autoantibodies to <scp>RNA</scp> polymerase <scp>III</scp> in a patient with systemic sclerosis successfully treated with corticosteroid and methotrexate. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1453-1454.	2.4	4
70	Annular Elastolytic Giant Cell Granuloma Successfully Treated with Minocycline Hydrochloride. Acta Dermato-Venereologica, 2015, 95, 756-757.	1.3	11
71	Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Research and Therapy, 2015, 17, 57.	3.5	48
72	DNA mismatch repair enzymes: Genetic defects and autoimmunity. Clinica Chimica Acta, 2015, 442, 102-109.	1.1	18

#	Article	IF	CITATIONS
73	Magnetic resonance imaging findings are useful for evaluating the three-dimensional development and follow-up of linear lupus erythematosus profundus. Lupus, 2015, 24, 1214-1216.	1.6	1
74	Diversity of humoral responses to the centromere proteins among HCV-related chronic liver disease, PBC and AIH patients. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 222-229.	1.5	5
75	High incidence of cancer in anti-small ubiquitin-like modifier activating enzyme antibody-positive dermatomyositis: Table 1. Rheumatology, 2015, 54, 1745-1747.	1.9	48
76	What are the "True―Pathogenic Anti-desmoglein Antibodies?. Acta Dermato-Venereologica, 2014, 95, 872, 874.	1.3	0
77	Brief Report: Autoantibodies to DNA Mismatch Repair Enzymes in Polymyositis/Dermatomyositis and Other Autoimmune Diseases: A Possible Marker of Favorable Prognosis. Arthritis and Rheumatology, 2014, 66, 3457-3462.	5.6	18
78	Annular Erythema Associated with Sjögren's Syndrome Preceding Overlap Syndrome of Rheumatoid Arthritis and Polymyositis with Anti-PL-12 Autoantibodies. Acta Dermato-Venereologica, 2014, 94, 470-471.	1.3	4
79	Extraordinarily large, giant spider angioma in an alcoholic cirrhotic patient. International Journal of Dermatology, 2014, 53, e119-21.	1.0	11
80	Solitary Organizing Pneumonia Mimicking Lung Adenocarcinoma in Systemic Sclerosis. Arthritis and Rheumatology, 2014, 66, 2648-2648.	5.6	3
81	Plasma CD147 reflects histological features in patients with lupus nephritis. Lupus, 2014, 23, 342-352.	1.6	28
82	ls the Measurement of Anti–PM″α Antibodies at Least as Important as That of Other Systemic Sclerosis–Specific Antibodies? Comment on the Article by D'Aoust et al. Arthritis and Rheumatology, 2014, 66, 3248-3248.	5.6	1
83	Detection of autoantibodies to periplakin and envoplakin in paraneoplastic pemphigus but not idiopathic pulmonary fibrosis using full-length recombinant proteins. Clinica Chimica Acta, 2014, 429, 14-17.	1.1	10
84	Author's Reply to "Detection of anti-periplakin autoantibodies during idiopathic pulmonary fibrosis― by Taillé et al Clinica Chimica Acta, 2014, 433, 194.	1.1	1
85	Nuclear envelope localization of <scp>R</scp> anâ€binding protein 2 and <scp>R</scp> anâ€ <scp>CTP</scp> aseâ€activating protein 1 in psoriatic epidermal keratinocytes. Experimental Dermatology, 2014, 23, 119-124.	2.9	6
86	High survival rate of harlequin ichthyosis in Japan. Journal of the American Academy of Dermatology, 2014, 70, 387-388.	1.2	16
87	Establishment of an ELISA to detect anti-glycyl-tRNA synthetase antibody (anti-EJ), a serological marker of dermatomyositis/polymyositis and interstitial lung disease. Clinica Chimica Acta, 2014, 431, 9-14.	1.1	9
88	What autoantibody tests should become widely available to help scleroderma diagnosis and management?. Arthritis Research and Therapy, 2013, 15, 116.	3.5	7
89	Possible roles of barrier-to-autointegration factor 1 in regulation of keratinocyte differentiation and proliferation. Journal of Dermatological Science, 2013, 71, 100-106.	1.9	19
90	Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity, 2013, 46, 279-284.	2.6	65

#	Article	IF	CITATIONS
91	Unilaterally dominant eosinophilic fasciitis after influenza vaccination. Journal of the American Academy of Dermatology, 2013, 69, e269-e270.	1.2	6
92	Cutaneous lupus mucinosis successfully treated with systemic corticosteroid and systemic tacrolimus combination therapy. Journal of the American Academy of Dermatology, 2013, 69, e200-e202.	1.2	6
93	Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clinical Rheumatology, 2013, 32, 395-398.	2.2	39
94	Low prevalence of autoantibodies to CENP-H, -I, -K, -L, -M, -N, -T and -U in a Japanese cohort of anti-centromere positive samples. Immunopharmacology and Immunotoxicology, 2013, 35, 57-63.	2.4	4
95	Low Prevalence of Anti-DFS70/LEDGF Antibodies in Patients with Dermatomyositis and Other Systemic Autoimmune Rheumatic Diseases. Journal of Rheumatology, 2013, 40, 92.2-93.	2.0	34
96	Paraneoplastic Pemphigus With Anti–Laminin-332 Autoantibodies in a Patient With Follicular Dendritic Cell Sarcoma. JAMA Dermatology, 2013, 149, 111.	4.1	8
97	The Majority of Generalized Pustular Psoriasis without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist. Journal of Investigative Dermatology, 2013, 133, 2514-2521.	0.7	251
98	Pulmonary mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome without interstitial pneumonia. International Journal of Rheumatic Diseases, 2013, 16, 780-782.	1.9	2
99	A New ELISA for Dermatomyositis Autoantibodies: Rapid Introduction of Autoantigen cDNA to Recombinant Assays for Autoantibody Measurement. Clinical and Developmental Immunology, 2013, 2013, 1-7.	3.3	27
100	Extraordinarily long linear cutaneous lupus erythematosus along the lines of Blaschko. Dermatology Online Journal, 2013, 19, 18960.	0.5	9
101	Clinical features of anti-TIF1-Â antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-Â or anti-Mi-2 autoantibodies. Rheumatology, 2012, 51, 1508-1513.	1.9	42
102	Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study. Rheumatology, 2012, 51, 129-133.	1.9	12
103	Severe Chilblain Lupus Is Associated with Heterozygous Missense Mutations of Catalytic Amino Acids or their Adjacent Mutations in the Exonuclease Domains of 3′-Repair Exonuclease 1. Journal of Investigative Dermatology, 2012, 132, 2855-2857.	0.7	17
104	Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology, 2012, 51, 1181-1187.	1.9	41
105	Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology, 2012, 51, 800-804.	1.9	95
106	Drug eruption due to sodium picosulfate. European Journal of Dermatology, 2012, 22, 410-411.	0.6	2
107	Autoantibodies to nuclear matrix protein 2/MJ in adult-onset dermatomyositis with severe calcinosis. Journal of the American Academy of Dermatology, 2012, 67, e167-e168.	1.2	7
108	A novel IL36RN/IL1F5 homozygous nonsense mutation, p.Arg10X, in a Japanese patient with adult-onset generalized pustular psoriasis. British Journal of Dermatology, 2012, 167, 699-701.	1.5	59

#	Article	IF	CITATIONS
109	LEDGF/DFS70 activates the MK2/IL6/STAT3 pathway in HaCaT. Journal of Dermatological Science, 2011, 63, 203-205.	1.9	6
110	Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Research and Therapy, 2011, 13, R214.	3.5	69
111	IgE and IgG4autoantibodies against DFS70/LEDGF in atopic dermatitis. Autoimmunity, 2011, 44, 511-519.	2.6	28
112	Cyclosporin A induces the unfolded protein response in keratinocytes. Archives of Dermatological Research, 2011, 303, 481-489.	1.9	6
113	Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatology, 2011, 147, 391.	1.4	293
114	Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in ILâ€1R2 in keratinocytes. Experimental Dermatology, 2010, 19, 730-735.	2.9	23
115	Anti-MDA5 and anti-TIF1-Î ³ antibodies have clinical significance for patients with dermatomyositis. Rheumatology, 2010, 49, 1726-1733.	1.9	237
116	Overexpression of LEDGF/DFS70 Induces IL-6 via p38 Activation in HaCaT Cells, Similar to that Seen in the Psoriatic Condition. Journal of Investigative Dermatology, 2010, 130, 2760-2767.	0.7	31
117	A Case of Perniosis with Antiphospholipid Antibody. Nishinihon Journal of Dermatology, 2010, 72, 201-203.	0.0	Ο
118	CENP-O, a Protein Localized at the Centromere Throughout the Cell Cycle, Is a Novel Target Antigen in Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 781-786.	2.0	13
119	Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology, 2009, 48, 1570-1574.	1.9	50
120	Successful topical hemotherapy with a new occlusive dressing for an intractable ulcer on the toe. Journal of Dermatology, 2009, 36, 245-248.	1.2	7
121	The Unfolded Protein Response Is Activated in Differentiating Epidermal Keratinocytes. Journal of Investigative Dermatology, 2009, 129, 2126-2135.	0.7	69
122	Evaluation of anti-ribosomal P protein immunoassay in Japanese patients with connective tissue diseases: comparison with an indirect immunofluorescence assay. Scandinavian Journal of Rheumatology, 2009, 38, 460-463.	1.1	8
123	Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole. Clinical and Experimental Rheumatology, 2009, 27, 15-21.	0.8	20
124	An evaluation of the efficacy of the toe brachial index measuring vascular involvement in systemic sclerosis and other connective tissue diseases. Clinical and Experimental Rheumatology, 2009, 27, 26-31.	0.8	17
125	Anti-SS-A/Ro antibody determination by indirect immunofluorescence and comparison of different methods of anti-nuclear antibody screening. Modern Rheumatology, 2008, 18, 585-592.	1.8	16
126	High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody–positive patients with autoimmune rheumatic disease. Lupus, 2008, 17, 171-176.	1.6	89

#	Article	IF	CITATIONS
127	Anti-SS-A/Ro antibody determination by indirect immunofluorescence and comparison of different methods of anti-nuclear antibody screening. Modern Rheumatology, 2008, 18, 585-592.	1.8	11
128	Diffuse Systemic Sclerosis with Severe Complications in Multiple Organs. Nishinihon Journal of Dermatology, 2008, 70, 610-613.	0.0	1
129	Comparison of ELISA with CENP-A and CENP-B for the detection of anti-centromere antibody. Clinical and Experimental Rheumatology, 2008, 26, 505.	0.8	1
130	LEDGF/DFS70, a Major Autoantigen of Atopic Dermatitis, Is a Component of Keratohyalin Granules. Journal of Investigative Dermatology, 2007, 127, 75-80.	0.7	34
131	Results of the Health Assessment Questionnaire for Japanese patients with systemic sclerosismeasuring functional impairment in systemic sclerosis versus other connective tissue diseases. Clinical and Experimental Rheumatology, 2007, 25, 367-72.	0.8	11
132	Anti-p80 coilin autoantibodies react with a conserved epitope and are associated with anti-DFS70/LEDGF autoantibodies. Journal of Autoimmunity, 2006, 26, 42-51.	6.5	26
133	HLA-associated production of anti-DFS70/LEDGF autoantibodies and systemic autoimmune disease. Journal of Autoimmunity, 2006, 26, 252-257.	6.5	18
134	Limited Cutaneous Systemic Sclerosis with Rapid Progression of Edematous Stiffness on the Forearms. Nishinihon Journal of Dermatology, 2006, 68, 24-27.	0.0	1
135	Improvement of Systemic Sclerosis Complicated with Interstitial Lung Disease by Intravenous Pulse Therapy with Cyclophosphamide. Nishinihon Journal of Dermatology, 2006, 68, 256-259.	0.0	1
136	Antinuclear antibodies. Autoimmunity, 2005, 38, 3-9.	2.6	36
137	A case of systemic lupus erythematosus: continued association of circulating prolactin levels with disease activity over a 4-year follow-up period. Modern Rheumatology, 2005, 15, 220-222.	1.8	3
138	A case of a childhood linear scleroderma with limb asymmetry. Modern Rheumatology, 2004, 14, 254-256.	1.8	3
139	Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis and Rheumatism, 2004, 50, 892-900.	6.7	176
140	Autoantigenicity of DFS70 is restricted to the conformational epitope of C-terminal alpha-helical domain. Journal of Autoimmunity, 2004, 23, 221-231.	6.5	47
141	Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients. Journal of Autoimmunity, 2004, 23, 257-266.	6.5	56
142	Antiâ€Ribosomalâ€P Antibodies in a Sjögren Syndrome Patient Associated with Lupus Erythematosus. Journal of Dermatology, 2004, 31, 811-814.	1.2	1
143	Autoantibodies in atopic dermatitis. Journal of Dermatological Science, 2001, 25, 171-178.	1.9	35
144	Identification of a Novel Kinesin-related Protein, KRMP1, as a Target for Mitotic Peptidyl-prolyl Isomerase Pin1. Journal of Biological Chemistry, 2001, 276, 37520-37528.	3.4	31

#	Article	IF	CITATIONS
145	Clinical and laboratory features of anticentromere antibody positive primary Sjögren's syndrome. Journal of Rheumatology, 2001, 28, 2238-44.	2.0	48
146	Spectrum of autoantibodies against a dynamin-related protein, dymple. Arthritis and Rheumatism, 2000, 43, 1516-1519.	6.7	4
147	Autoepitopes on autoantigen centromere protein-A (CENP-A) are restricted to the N-terminal region, which has no homology with histone H3. Clinical and Experimental Immunology, 2000, 120, 218-223.	2.6	29
148	Differences in specificities of anti-centromere sera for the monomeric and dimeric C-terminal peptides of human centoromere protein C. International Immunology, 2000, 12, 1431-1437.	4.0	7
149	Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. Journal of Allergy and Clinical Immunology, 2000, 105, 1211-1220.	2.9	207
150	A newly identified anti-nuclear antobody "anti-DFS 70 antibodyâ€, its clinical significance. Japanese Journal of Clinical Immunology, 2000, 23, 425-434.	0.0	0
151	Clinical Features and IgG Subclass Distribution of Anti-p80 Coilin Antibodies. Journal of Autoimmunity, 1999, 13, 225-232.	6.5	12
152	Anti-annexin V antibodies and digital ischemia in patients with scleroderma. Journal of Rheumatology, 1999, 26, 2168-72.	2.0	24
153	cDNA cloning of a novel autoantigen targeted by a minor subset of anti-centromere antibodies. Clinical and Experimental Immunology, 1998, 111, 372-376.	2.6	10
154	Autoantibody to Thioredoxin Reductase in an Ovarian Cancer Patient. Biochemical and Biophysical Research Communications, 1998, 242, 267-271.	2.1	15
155	Dymple, a Novel Dynamin-like High Molecular Weight GTPase Lacking a Proline-rich Carboxyl-terminal Domain in Mammalian Cells. Journal of Biological Chemistry, 1998, 273, 1044-1051.	3.4	48
156	Epitope mapping of human centromere autoantigen centromere protein C (CENP-C); heterogeneity of anti-CENP-C response in rheumatic diseases. Journal of Rheumatology, 1998, 25, 474-81.	2.0	9
157	Low Frequency of Autoantibodies against Ki-67 Antigen in Japanese Patients with Systemic Autoimmune Diseases. Journal of Autoimmunity, 1997, 10, 499-503.	6.5	7
158	Identification of a novel nuclear speckle-type protein, SPOP. FEBS Letters, 1997, 418, 23-26.	2.8	116
159	Expression cloning and intracellular localization of a human ZF5 homologue. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1997, 1352, 23-26.	2.4	19
160	Thrombopoietin-induced Polyploidization of Bone Marrow Megakaryocytes Is Due to a Unique Regulatory Mechanism in Late Mitosis. Journal of Cell Biology, 1997, 139, 449-457.	5.2	125
161	Human Homolog of Drosophila Heterochromatin-Associated Protein 1 (HP1) Is a DNA-Binding Protein Which Possesses a DNA-Binding Motif with Weak Similarity to That of Human Centromere Protein C (CENP-C). Journal of Biochemistry, 1996, 120, 153-159.	1.7	40
162	A Novel Kinase Cascade Mediated by Mitogen-activated Protein Kinase Kinase 6 and MKK3. Journal of Biological Chemistry, 1996, 271, 13675-13679.	3.4	417

#	Article	IF	CITATIONS
163	A Charged Segment Mainly Composed of Basic Amino Acids Forms an Autoepitope of CENP-A. Clinical Immunology and Immunopathology, 1996, 78, 86-89.	2.0	12
164	Differential apoptotic pattern induced by photodynamic therapy and cisplatin in human squamous cell carcinoma cell line. Archives of Dermatological Research, 1996, 289, 52-54.	1.9	10
165	Clinical features of anti hromo antibodies associated with anti entromere antibodies. Clinical and Experimental Immunology, 1996, 105, 285-290.	2.6	23
166	Epitope analysis of chromo antigen and clinical features in a subset of patients with anti-centromere antibodies. Molecular Biology Reports, 1996, 23, 147-151.	2.3	9
167	A Cell-Cycle Nuclear Autoantigen Containing Wd-40 Motifs Expressed Mainly in S and G2-Phase Cells. Biochemical and Biophysical Research Communications, 1995, 207, 1029-1037.	2.1	82
168	Human Centromere Protein C (CENP-C) Is a DNA-Binding Protein Which Possesses a Novel DNA-Binding Motif1. Journal of Biochemistry, 1994, 116, 877-881.	1.7	83
169	Synthetic compound peptide simulating antigenicity of conformation-dependent autoepitope. Journal of Biological Chemistry, 1994, 269, 18529-18534.	3.4	22
170	Synthetic compound peptide simulating antigenicity of conformation-dependent autoepitope. Journal of Biological Chemistry, 1994, 269, 18529-34.	3.4	20
171	Autoantibody-defined epitopes on nuclear antigens are conserved, conformation-dependent and active site regions. Clinical and Experimental Rheumatology, 1994, 12 Suppl 11, S27-31.	0.8	7
172	Centromere protein B assembles human centromeric alpha-satellite DNA at the 17-bp sequence, CENP-B box Journal of Cell Biology, 1992, 116, 585-596.	5.2	208
173	A human centromere protein, CENP-B, has a DNA binding domain containing four potential alpha helices at the NH2 terminus, which is separable from dimerizing activity Journal of Cell Biology, 1992, 119, 1413-1427.	5.2	125
174	The Clinical Expression in Anticentromere Antibodyâ€positive Patients Is Not Specified by the Epitope Recognition of CENPâ€B Antigen. Journal of Dermatology, 1992, 19, 584-591.	1.2	7
175	Anti-Helix-Loop-Helix Domain Antibodies: Discovery of Autoantibodies That Inhibit DNA Binding Activity of Human Centromere Protein B (CENP-B)1. Journal of Biochemistry, 1992, 111, 478-483.	1.7	33
176	Anticentromere-protein-B-DNA complex activities in anticentromere antibody-positive patients. Archives of Dermatological Research, 1992, 284, 396-399.	1.9	2
177	Purification of a Human Centromere Antigen (CENP-B) and Application of DNA Immunoprecipitation to Quantitative Assay for Anti-CENP-B Antibodies. Journal of Investigative Dermatology, 1991, 97, 378-380.	0.7	7
178	The heterogeneity of anticentromere antibodies in immunoblotting analysis. Journal of Rheumatology, 1990, 17, 1042-7.	2.0	49
179	A human centromere antigen (CENP-B) interacts with a short specific sequence in alphoid DNA, a human centromeric satellite Journal of Cell Biology, 1989, 109, 1963-1973.	5.2	651
180	UVB-Induced Skin Autoinflammation Due to Nlrp1b Mutation and Its Inhibition by Anti-IL-1β Antibody. Frontiers in Immunology, 0, 13, .	4.8	3